Altimmune, Inc. (ALT)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

-5M 0 5M 10M 15M Q4 '16: 3.2M Q1 '17: 3M Q2 '17: 5.3M Q3 '17: 9M Q4 '17: 10.7M Q1 '18: 13.1M Q2 '18: 12.5M Q3 '18: 10.6M Q4 '18: 10.3M Q1 '19: 10.6M Q2 '19: 9.8M Q3 '19: 7.8M Q4 '19: 5.8M Q1 '20: 5.1M Q2 '20: 4.2M Q3 '20: 6.4M Q4 '20: 8.2M Q1 '21: 6.8M Q2 '21: 6.2M Q3 '21: 3.4M Q4 '21: 4.4M Q1 '22: 3.6M Q2 '22: 3.5M Q3 '22: 3.3M Q4 '22: -68K Q1 '23: -79K Q2 '23: -81K Q3 '23: 279K Q4 '23: 426K Q1 '24: 410K Q2 '24: 409K Q3 '24: 52K Q4 '24: 20K Q1 '25: 20K Q2 '25: 20K Q3 '25: 20K Q4 '25: 41K Q1 '17 Q2 '18 Q3 '19 Q4 '20 Q1 '22 Q2 '23 Q3 '24 Q4 '25

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-120M -80M -40M 0 40M 80M 120M Q3 '16: -8.6M Q4 '16: -13.2M Q1 '17: -16.4M Q2 '17: -18.8M Q3 '17: -45M Q4 '17: -52M Q1 '18: -53.5M Q2 '18: -54.9M Q3 '18: -28.1M Q4 '18: -42.8M Q1 '19: -39.2M Q2 '19: -37.3M Q3 '19: -44.5M Q4 '19: -21.5M Q1 '20: -26.4M Q2 '20: -41.3M Q3 '20: -48.4M Q4 '20: -54.8M Q1 '21: -62.4M Q2 '21: -68.8M Q3 '21: -83.7M Q4 '21: -96.9M Q1 '22: -101.6M Q2 '22: -97.1M Q3 '22: -88.6M Q4 '22: -87.7M Q1 '23: -90M Q2 '23: -87.6M Q3 '23: -85.4M Q4 '23: -95.9M Q1 '24: -101M Q2 '24: -109.7M Q3 '24: -111.9M Q4 '24: -103.2M Q1 '25: -98.2M Q2 '25: -94.4M Q3 '25: -90.5M Q4 '25: -94.5M Q1 '26: -96.9M Q2 '26: -100.2M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income TTM

-120M -80M -40M 0 40M 80M 120M Q3 '16: -8.9M Q4 '16: 70.2M Q1 '17: 66.8M Q2 '17: 65.3M Q3 '17: 40.2M Q4 '17: -46.4M Q1 '18: -45M Q2 '18: -51M Q3 '18: -23.5M Q4 '18: -39.2M Q1 '19: -38.1M Q2 '19: -32.3M Q3 '19: -40.9M Q4 '19: -20.5M Q1 '20: -22.3M Q2 '20: -35.7M Q3 '20: -42.5M Q4 '20: -49M Q1 '21: -60M Q2 '21: -68.1M Q3 '21: -83.8M Q4 '21: -97.1M Q1 '22: -101.7M Q2 '22: -96.9M Q3 '22: -86.9M Q4 '22: -84.7M Q1 '23: -85.4M Q2 '23: -81.3M Q3 '23: -78.5M Q4 '23: -88.4M Q1 '24: -92.8M Q2 '24: -101.3M Q3 '24: -103.5M Q4 '24: -95.1M Q1 '25: -90.2M Q2 '25: -87.7M Q3 '25: -83.9M Q4 '25: -88.1M Q1 '26: -91.1M Q2 '26: -91.8M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-90M -60M -30M 0 30M 60M 90M Q3 '16: -6.7M Q4 '16: -6.4M Q1 '17: -8.3M Q2 '17: -14.5M Q3 '17: -16.9M Q4 '17: -20.2M Q1 '18: -20.4M Q2 '18: -12.3M Q3 '18: -9M Q4 '18: -9.4M Q1 '19: -7.9M Q2 '19: -11.4M Q3 '19: -12.8M Q4 '19: -9.6M Q1 '20: -11.8M Q2 '20: -15.9M Q3 '20: -23M Q4 '20: -34.3M Q1 '21: -49.5M Q2 '21: -61.3M Q3 '21: -69.6M Q4 '21: -78.2M Q1 '22: -72.2M Q2 '22: -70M Q3 '22: -67.2M Q4 '22: -62.6M Q1 '23: -68.5M Q2 '23: -71.1M Q3 '23: -76.6M Q4 '23: -75.8M Q1 '24: -72.8M Q2 '24: -71.5M Q3 '24: -78.1M Q4 '24: -79.8M Q1 '25: -80.3M Q2 '25: -81.6M Q3 '25: -66.4M Q4 '25: -67.5M Q1 '26: -71.6M Q2 '26: -76.5M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow TTM

-105M -70M -35M 0 35M 70M 105M Q4 '14: -8.6M Q1 '15: -9M Q2 '15: -5.8M Q3 '15: -5M Q4 '15: -3.3M Q1 '16: -1.9M Q2 '16: -6.2M Q3 '16: -6.8M Q4 '16: -6.5M Q1 '17: -8.5M Q2 '17: -14.7M Q3 '17: -17M Q4 '17: -20.3M Q1 '18: -21.2M Q2 '18: -13.1M Q3 '18: -10M Q4 '18: -10.4M Q1 '19: -8.3M Q2 '19: -11.5M Q3 '19: -12.8M Q4 '19: -9.6M Q1 '20: -11.9M Q2 '20: -16M Q3 '20: -23.1M Q4 '20: -34.5M Q1 '21: -53.9M Q2 '21: -73.3M Q3 '21: -81.6M Q4 '21: -90.4M Q1 '22: -80.1M Q2 '22: -70.2M Q3 '22: -67.5M Q4 '22: -62.7M Q1 '23: -68.6M Q2 '23: -71.3M Q3 '23: -76.7M Q4 '23: -75.9M Q2 '26: -76.6M Q2 '15 Q3 '16 Q4 '17 Q1 '19 Q2 '20 Q3 '21 Q4 '22 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 70M 140M 210M Q1 '14: 53M Q1 '15: 64M Q2 '15: 63.7M Q3 '15: 64.2M Q1 '16: 64.4M Q2 '16: 65.2M Q3 '16: 65.8M Q1 '21: 38.9M Q2 '21: 41.4M Q3 '21: 41.4M Q1 '22: 44M Q2 '22: 47.5M Q3 '22: 49.3M Q1 '23: 50.1M Q2 '23: 50.7M Q3 '23: 53.6M Q1 '24: 70.8M Q2 '24: 70.9M Q3 '24: 71.1M Q1 '25: 75.5M Q2 '25: 81.5M Q3 '25: 89.4M Q1 '26: 124.5M Q2 '26: 185.4M Q2 '15 Q2 '16 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-105.00 -70.00 -35.00 0.00 35.00 70.00 105.00 Q2 '15: -0.14 Q3 '15: -0.08 Q4 '15: -0.06 Q1 '16: -0.10 Q3 '17: -61.36 Q4 '17: -78.66 Q1 '18: -85.47 Q2 '18: -95.50 Q3 '18: -35.66 Q4 '18: -15.16 Q1 '19: -7.94 Q2 '19: 2.09 Q3 '19: 3.08 Q4 '19: -1.52 Q1 '20: -1.51 Q2 '20: -2.19 Q3 '20: -1.99 Q4 '20: -1.91 Q1 '21: -2.03 Q2 '21: -1.69 Q3 '21: -1.96 Q4 '21: -2.35 Q1 '22: -2.41 Q2 '22: -2.23 Q3 '22: -1.90 Q4 '22: -1.78 Q1 '23: -1.74 Q2 '23: -1.64 Q3 '23: -1.55 Q4 '23: -1.67 Q1 '24: -1.61 Q2 '24: -1.64 Q3 '24: -1.57 Q4 '24: -1.34 Q1 '25: -1.26 Q2 '25: -1.18 Q3 '25: -1.07 Q4 '25: -1.00 Q1 '26: -0.92 Q2 '26: -0.77 Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.